

Jaymin B Morjaria

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7761229/publications.pdf>

Version: 2024-02-01

38
papers

1,536
citations

471371

17
h-index

330025

37
g-index

38
all docs

38
docs citations

38
times ranked

2013
citing authors

#	ARTICLE	IF	CITATIONS
1	Efficiency and Safety of an eElectronic cigarette (ECLAT) as Tobacco Cigarettes Substitute: A Prospective 12-Month Randomized Control Design Study. PLoS ONE, 2013, 8, e66317.	1.1	576
2	Effectiveness and tolerability of electronic cigarette in real-life: a 24-month prospective observational study. Internal and Emergency Medicine, 2014, 9, 537-546.	1.0	141
3	Effect of Smoking Abstinence and Reduction in Asthmatic Smokers Switching to Electronic Cigarettes: Evidence for Harm Reversal. International Journal of Environmental Research and Public Health, 2014, 11, 4965-4977.	1.2	118
4	Persisting long term benefits of smoking abstinence and reduction in asthmatic smokers who have switched to electronic cigarettes. Discovery Medicine, 2016, 21, 99-108.	0.5	73
5	Health effects in COPD smokers who switch to electronic cigarettes: a retrospective-prospective 3-year follow-up. International Journal of COPD, 2018, Volume 13, 2533-2542.	0.9	61
6	Changes in breathomics from a 1-year randomized smoking cessation trial of electronic cigarettes. European Journal of Clinical Investigation, 2016, 46, 698-706.	1.7	57
7	Mepolizumab in the management of severe eosinophilic asthma in adults: current evidence and practical experience. Therapeutic Advances in Respiratory Disease, 2018, 12, 175346661880849.	1.0	53
8	Inhaled Corticosteroid use and the Risk of Pneumonia and COPD Exacerbations in the UPLIFT Study. Lung, 2017, 195, 281-288.	1.4	52
9	COPD smokers who switched to e-cigarettes: health outcomes at 5-year follow up. Therapeutic Advances in Chronic Disease, 2020, 11, 204062232096161.	1.1	47
10	Baseline Results of the West London lung cancer screening pilot study – Impact of mobile scanners and dual risk model utilisation. Lung Cancer, 2020, 148, 12-19.	0.9	37
11	Treatment of Allergic Rhinitis as a Strategy for Preventing Asthma. Current Allergy and Asthma Reports, 2018, 18, 23.	2.4	35
12	Health outcomes in COPD smokers using heated tobacco products: a 3-year follow-up. Internal and Emergency Medicine, 2021, 16, 687-696.	1.0	33
13	Biologic and pharmacologic therapies in clinical development for the inflammatory response in COPD. Drug Discovery Today, 2010, 15, 396-405.	3.2	32
14	Autoptic identification of disseminated mucormycosis in a young male presenting with cerebrovascular event, multi-organ dysfunction and COVID-19 infection. IDCases, 2021, 25, e01172.	0.4	32
15	Preventing Progression of Allergic Rhinitis to Asthma. Current Allergy and Asthma Reports, 2014, 14, 412.	2.4	27
16	E-cigarettes in patients with COPD: current perspectives. International Journal of COPD, 2017, Volume 12, 3203-3210.	0.9	27
17	Emerging therapeutic strategies in COPD. Drug Discovery Today, 2015, 20, 371-379.	3.2	17
18	Asthma phenotypes: do cough and wheeze predict exacerbations in persistent asthma?. European Respiratory Journal, 2017, 50, 1701366.	3.1	13

#	ARTICLE	IF	CITATIONS
19	Biologic agents for severe asthma patients: clinical perspectives and implications. Internal and Emergency Medicine, 2018, 13, 155-176.	1.0	13
20	Vilanterol trifenatate for the treatment of COPD. Expert Review of Respiratory Medicine, 2016, 10, 719-731.	1.0	12
21	Is opiate action in cough due to sedation?. Therapeutic Advances in Chronic Disease, 2014, 5, 200-205.	1.1	10
22	Novel antitussive strategies. Drug Discovery Today, 2013, 18, 380-388.	3.2	9
23	Profile of inhaled glycopyrronium bromide as monotherapy and in fixed-dose combination with indacaterol maleate for the treatment of COPD. International Journal of COPD, 2015, 10, 111.	0.9	9
24	Bilateral lower limb weakness: a cerebrovascular consequence of covid-19 or a complication associated with it?. Internal and Emergency Medicine, 2020, 15, 901-905.	1.0	9
25	Unusual asthma syndromes and their management. Therapeutic Advances in Chronic Disease, 2011, 2, 249-264.	1.1	6
26	Dupilumab and tezepelumab in severe refractory asthma: new opportunities. Therapeutic Advances in Chronic Disease, 2022, 13, 204062232210973.	1.1	6
27	Symptoms and exacerbations in asthma: an apparent paradox?. Therapeutic Advances in Chronic Disease, 2019, 10, 204062231988438.	1.1	5
28	An evaluation of mepolizumab for the treatment of severe asthma. Expert Opinion on Biological Therapy, 2019, 19, 491-500.	1.4	5
29	Pneumothorax: a tale of pain or spontaneity. Therapeutic Advances in Chronic Disease, 2014, 5, 269-273.	1.1	3
30	Airway responsiveness to adenosine after a single dose of fluticasone propionate discriminates asthma from COPD. Pulmonary Pharmacology and Therapeutics, 2014, 27, 70-75.	1.1	3
31	Bilateral chylothorax: an unusual complication of cervical rib resection. Therapeutic Advances in Chronic Disease, 2015, 6, 29-33.	1.1	3
32	The holistic perspective of chronic obstructive pulmonary disease: doubt some more. Therapeutic Advances in Chronic Disease, 2010, 1, 37-41.	1.1	2
33	Fluticasone furoate and vilanterol for COPD. Lancet Respiratory Medicine, the, 2013, 1, e21.	5.2	2
34	Clinicopharmacological profile of the fixed-dose combination of aclidinium bromide and formoterol fumarate in the management of chronic obstructive pulmonary disease. Therapeutic Advances in Respiratory Disease, 2015, 9, 56-68.	1.0	2
35	Investigational beta-2 adrenergic agonists for the treatment of chronic obstructive pulmonary disease. Expert Opinion on Investigational Drugs, 2017, 26, 319-329.	1.9	2
36	The discovery and development of aclidinium bromide for the treatment of chronic obstructive pulmonary disease. Expert Opinion on Drug Discovery, 2018, 13, 563-577.	2.5	2

#	ARTICLE	IF	CITATIONS
37	Autonomic dysregulation: a mechanism of asthma death. <i>European Respiratory Journal</i> , 2014, 44, 1357-1360.	3.1	1
38	<i>Nocardia cyriacigeorgica</i> in an immunocompetent patient. <i>Therapeutic Advances in Respiratory Disease</i> , 2015, 9, 28-30.	1.0	1